SoftWriters’ FrameworkLTC® Platform Integrates FDB’s Meducation® Solution to Enable Multilingual Prescription Labeling

Leading Purpose-Built Pharmacy Management System for Long-Term Care Facilities to Translate Prescription Instructions into Nearly 30 Languages, Improving Patient Understanding and Medication Adherence

FDB (First Databank, Inc.), the leading provider of drug and medical device knowledge that helps healthcare professionals make precise decisions, today announced an agreement with SoftWriters to integrate FDB’s Meducation® solution into its FrameworkLTC® pharmacy management platform to seamlessly translate prescription labels into any of nearly 30 preferred languages requested by patients.

The integration aligns with new state regulations, most recently announced in Nevada and Oregon, that require pharmacies to offer prescription labels in a language other than English at the request of the patient or caregiver. Oregon’s law went into effect this year and Nevada’s law was approved by its governor this year and will go into effect in July 2022. California’s and New York’s multilingual prescription label laws each have been on the books for several years.

Research has shown that patients receiving simplified, personalized medication instructions in their primary language demonstrate significantly greater understanding of their prescriptions than those receiving generic instructions.

“More and more state leaders are recognizing that offering prescription labels and educational materials in a patient’s preferred language can improve their health literacy and adherence to medication regimens,” said Charles Lee, MD, Senior Director of Clinical Knowledge for FDB. “SoftWriters is taking the lead in this regard by integrating FDB’s Meducation solution into its market-leading platform, which will save pharmacists time in fulfilling orders and improve patients’ understanding of their therapies, leading to better outcomes.”

Accessing Meducation’s translated prescriptions capability is simple for pharmacists using FrameworkLTC and eliminates the need to deviate from their existing fulfillment workflow. When the physician submits the prescription order, including the dosing and refill instructions, or “sig,” Meducation’s Natural Language Processing (NLP) capabilities transform the sig—which can come in one of millions of variations—into a standardized, translated format.

When using this new solution, a pharmacist simply selects the patient’s preferred language within FrameworkLTC that is powered by FDB’s Meducation API. The translation capability updates the label to the preferred language in less than a second. In addition, the image-based format provides a method to support older labeling printers that may not have built-in support for some fonts or right-to-left languages.

“Multilingual support is another example of how SoftWriters is dedicated to meeting a market need while improving our user experience through the continual optimization of our FrameworkLTC purpose-built pharmacy management platform,” said Deepika Devarajan, Vice President, Product at SoftWriters. “FDB’s robust and seamless solution is the perfect addition to our highly automated platform that we anticipate will continue to streamline pharmacist workflows and drive patient outcomes.”

Complete Patient Medication Education Solution

Meducation includes more than prescription label translation support. It is a complete patient medication education and engagement solution that can enable organizations to provide simplified, personalized medication instructions to all patients. All material is written at a 5th to 8th grade level with supporting pictograms and calendars, and is available in a range of font sizes. Beyond printed materials, a patient’s Meducation content can be accessed through a web browser, patient portal or mobile app.

“Multilingual support is an important element of our broader patient medication education solution and one we are pleased to share with more pharmacy teams across all healthcare settings, offering additional languages as they become available,” said Dr. Lee. “Not only does the near-real-time language translation save pharmacists time and help them practice more efficiently, but it also helps them better care for and communicate with and support the patient and their caregivers.”

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy